在耐火性肌痛性肌痛症中使用eculizumab:现实世界的单中心体验
Dario Ricciardi1,2, Carmen Erra3, Francesco Tuccillo1
1UOC Neurophysiopathology, AORN Cardarelli, Via Antonio Cardarelli 9, Naples, 80131, Italy.
概括
在意大利的一项实践研究中,eculizumab有效治疗耐火性全般化肌痛性肌痛症 (rMG),显著减少症状和免疫抑制剂的使用. 这种疗法提供了快速的临床改善,并减少了恶化.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓灰质炎 (MG) 是一种影响神经肌肉结合的自身免疫性疾病.
- 耐药性MG (rMG) 患者对标准免疫抑制疗法表现出不充分的反应或不耐受.
- 作为C5补剂抑制剂的eculizumab提供了针对rMG的向治疗选择.
研究的目的:
- 评估eculizumab在意大利rMG患者中的实际有效性和安全性.
- 在一年的随访期内评估临床结果和治疗调整.
主要方法:
- 对21名接受eculizumab治疗的rMG患者的回顾性分析 (2022年11月 - 2024年5月).
- 临床评估使用MG-ADL,QMG,MGFA和PIS尺度在1,3,6和12个月.
- 救援疗法的记录和背景免疫抑制治疗的变化.
主要成果:
- 在第一个月内观察到MG-ADL和QMG得分的临床上有意义的减少,并且持续.
- 肌性恶化和危机显著减少,大多数患者停止IVIg治疗.
- 显著减少每日普得尼松剂量和其他免疫抑制疗法.
结论:
- 埃奎利祖马布在现实世界rMG群体中证明了安全性和有效性.
- 临床结果的快速改善支持eculizumab在管理rMG中的作用.
- 埃奎利祖马布促进了显著的免疫抑制剂节约效益,改善了患者管理.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
05:55Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
761
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:15Myasthenia Gravis: Diagnostic Tests
661
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
661